Drug, across the briefings
Dabrafenib across 7 cancers
Dabrafenib appears in 7 of the briefings; its FDA label names 3 of those diseases.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Lung cancer | label names disease | approved on BRAF | 10 | 4 |
| Melanoma | label names disease | approved on BRAF | 78 | 15 |
| Thyroid cancer | label names disease | approved on BRAF | 16 | 7 |
| Cholangiocarcinoma | approved on BRAF | — | — | |
| Colorectal cancer | approved on BRAF | 10 | 6 | |
| Gastrointestinal stromal tumour | approved on BRAF | 1 | 0 | |
| Small intestine cancer | approved on BRAF | 1 | 0 |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.